Hennion & Walsh Asset Management’s Avidity Biosciences RNAM Stock Holding History

Hennion & Walsh Asset Management’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-62,423	Closed	-$1.84M	–	947
2025 Q1	$1.84M	Sell	62,423 -14,387	-19%	-$448K	0.08%	293
2024 Q4	$2.23M	Sell	76,810 -1,428	-2%	-$59.7K	0.1%	259
2024 Q3	$3.59M	Sell	78,238 -975	-1%	-$42.3K	0.17%	151
2024 Q2	$3.24M	Buy	79,213 +6,241	+9%	+$179K	0.17%	150
2024 Q1	$1.86M	Buy	72,972 +1,777	+2%	+$27.8K	0.1%	269
2023 Q4	$644K	Buy	71,195 +4,975	+8%	+$33.3K	0.04%	507
2023 Q3	$422K	Buy	66,220 +31,277	+90%	+$269K	0.03%	563
2023 Q2	$388K	Buy	+34,943	New	+$438K	0.02%	588

Other funds holding RNAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hennion & Walsh Asset Management's RNAM Position: Q2 2025 in Review

Hennion & Walsh Asset Management sold out of Avidity Biosciences (RNAM) in Q2 2025, closing a stake of 62,423 shares — an estimated $1.84M sold.

Hennion & Walsh Asset Management first reported a position in RNAM in Q2 2023 and held it in 8 quarters. The position peaked at $3.59M in Q3 2024. 206 funds tracked by Wall St. Rank hold RNAM as of Q2 2025.

Hennion & Walsh Asset Management reported no remaining Avidity Biosciences position as of Q2 2025 after selling out during the quarter.
Hennion & Walsh Asset Management sold 62,423 Avidity Biosciences shares in Q2 2025, an estimated $1.84M.
Hennion & Walsh Asset Management first reported a position in Avidity Biosciences in Q2 2023 and held it in 8 quarters.
Hennion & Walsh Asset Management's Avidity Biosciences position peaked at $3.59M in Q3 2024.
206 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2025.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.